Change is good. Health Technology Assessment itself is constituted of many change components starting from research, which is looking for evidence to change something, to decision-making, which is changing something from its previous state to a new one. With the half of 2017 gone by, many new change

Summary of the HTAsiaLink 2018  In 2018, was co-hosted by the Health Intervention and Technology Assessment Program (HITAP) and the Health Technology Assessment Program at Mahidol University from 8-11 May 2018 in Chiang Mai, Thailand. The theme of the conference was “Testing Treatments: Strengthe

In the era that most of the countries are moving toward universal health coverage (UHC), there is no doubt that every country experiences gap between their citizen’s health needs and what is economically achievable by government, especially in speedily advancement in health technology field. Hence p

Economic evaluation (EE) is a field that is increasingly needed in many countries to support health decision making for priority setting and resource allocation. Although the core concept of EE is simple it is a comparison of at least 2 interventions in terms of costs and benefits – the practicaliti

In the world that is full of unpredictable and countless number of uncertainties, it is a great challenge that we have to observe and adapt in order to overcome such swiftly shifting challenges. However, over the past three years, people around the world have been facing one of the most critic

Details: The 11th HTAsiaLink Annual Conference took place in Putrajaya Malaysia, centered around the theme “Reshaping and Reshifting HTA in Navigating the Future Landscape”. Key discussions revolved around accelerating access to technologies, evaluating public health interventions and addressing ch

The 10th HTAsiaLink Annual Conference is the first physical conference after the pandemic hit for HTAsiaLink network. Under the theme ‘The Role of HTA in the New Normal: Driving the post-COVID health systems through evidence-informed decisions,’ a broad range of discussions were sparked and would co

Human papillomavirus vaccine introduction in low and middle income countries: guidance on the use of cost-effectiveness models Mark Jit1, Nadia Demarteau2†, Elamin Elbasha3†, Gary Ginsberg4†, Jane Kim5†, Naiyana Praditsitthikorn6†, Edina Sinanovic7† and Raymond Hutubessy8* † Contributed equally 8

Government use licenses in Thailand: an assessment of the health and economic impacts Inthira Yamabhai, Adun Mohara, Sripen Tantivess*, Kakanang Chaisiri and Yot Teerawattananon. Health Intervention and Technology Assessment Program (HITAP) Background Between 2006 and 2008, Thailand’s Mi

Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand Pattara Leelahavarong1*, Yot Teerawattananon1, Pitsaphun Werayingyong1, Chutima Akaleephan2, Nakorn Premsri3, Chawetsan Namwat3, Wiwat Peerapatanapoki